Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Follicular or Mantle Cell Lymphoma

NCT01678417 is registered in ClinicalTrials.gov with Korea Cancer Center Hospital as lead sponsor.

NCT NCT01678417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01678417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Lead sponsor
Korea Cancer Center Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2012
Completion date
June 30, 2017
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory follicular lymphoma or mantle cell lymphoma